Multiple myeloma in a murine syngeneic model:modulation of growth and angiogenesis by a monoclonal antibody to kininogen.
Cancer Immunol. Immunother., Jul;55(7):797-807 (2006)
Domain 5 of cleaved high molecular weight kininogen inhibits endothelial cell migration through Akt.
Thromb. Haemost., Sep;94(3):606-14 (2005)
Truncated and microparticle-free soluble tissue factor bound to peripheral monocytes preferentially activate factor VII.
Thromb. Haemost., Mar;95(3):462-8 (2006)
Are hemostasis and thrombosis two sides of the same coin?
J. Exp. Med., Mar;203(3):493-5 (2006)
[High molecular weight kininogen in inflammation and angiogenesis: a review of its properties and therapeutic applications].
Rev. Invest. Clin., 57(6):802-13 (2005)
Regulation of angiogenesis by the kallikrein-kinin system.
Curr. Pharm. Des., 12(21):2599-607 (2006)
New insights from the structure-function analysis of the catalytic region of human platelet phosphodiesterase 3A: a role for the unique 44-amino acid insert.
J. Biol. Chem., Sep;281(39):29236-44 (2006)
High-molecular-weight kininogen fragments stimulate the secretion of cytokines and chemokines through uPAR, Mac-1, and gC1qR in monocytes.
Arterioscler. Thromb. Vasc. Biol., Oct;26(10):2260-6 (2006)
Antithrombotic activity of kininogen is mediated by inhibitory effects of domain 3 during arterial injury in vivo.
Am. J. Physiol. Heart Circ. Physiol., Jun;292(6):H2959-65 (2007)
Thrombin regulates intracellular cyclic AMP concentration in human platelets through phosphorylation/activation of phosphodiesterase 3A.
Blood., Sep;110(5):1475-82 (2007)
Kininostatin associates with membrane rafts and inhibits alpha(v)beta3 integrin activation in human umbilical vein endothelial cells.
Arterioscler. Thromb. Vasc. Biol., Sep;27(9):1968-75 (2007)
Fifty years of research on the plasma kallikrein-kinin system: from protein structure and function to cell biology and in-vivo pathophysiology.
Thromb. Haemost., Jul;98(1):77-83 (2007)
The inhibition of tube formation in a collagen-fibrinogen, three-dimensional gel by cleaved kininogen (HKa) and HK domain 5 (D5) is dependent on Src family kinases.
Exp. Cell Res., Feb;314(4):774-88 (2008)
A new nonhydrolyzable reactive cGMP analogue, (Rp)-guanosine-3',5'-cyclic-S-(4-bromo-2,3-dioxobutyl)monophosphorothioate, which targets the cGMP binding site of human platelet PDE3A.
Bioorg. Chem., Jun;36(3):141-7 (2008)
The inhibitory effect of HKa in endothelial cell tube formation is mediated by disrupting the uPA-uPAR complex and inhibiting its signaling and internalization.
Am. J. Physiol., Cell Physiol., Jul;295(1):C257-67 (2008)
Mechanisms by which cleaved kininogen inhibits endothelial cell differentiation and signalling.
Thromb. Haemost., Nov;104(5):875-85 (2010)
Inhibition of metastasis of syngeneic murine melanoma in vivo and vasculogenesis in vitro by monoclonal antibody C11C1 targeted to domain 5 of high molecular weight kininogen.
Cancer Immunol. Immunother., Dec;59(12):1885-93 (2010)
A role for plasma kallikrein-kinin system activation in the synovial recruitment of endothelial progenitor cells in arthritis.
Apoptotic effect of cleaved high molecular weight kininogen is regulated by extracellular matrix proteins.
J. Cell. Biochem., Jun;89(3):622-32 (2003)
The mutation Ser511Asn leads to N-glycosylation and increases the cleavage of high molecular weight kininogen in rats genetically susceptible to inflammation.
Blood., Oct;102(8):2835-42 (2003)